Drugs targeting the vascular endothelial growth factor (VEGF) pathway represent a successful therapeutic option for several solid malignancies, but are burdened by the risk of developing cardiovascular (CV) and renal adverse events (CVAEs).
Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program / Tini, G.; Sarocchi, M.; Sirello, D.; Murialdo, R.; Fornarini, G.; Buzzatti, G.; Boccardo, F.; Arboscello, E.; Porto, I.; Ameri, P.; Spallarossa, P.. - In: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. - ISSN 2047-4873. - 28:9(2021), pp. 38-40. [10.1177/2047487320923056]
Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program
Tini G.;
2021
Abstract
Drugs targeting the vascular endothelial growth factor (VEGF) pathway represent a successful therapeutic option for several solid malignancies, but are burdened by the risk of developing cardiovascular (CV) and renal adverse events (CVAEs).| File | Dimensione | Formato | |
|---|---|---|---|
|
Tini_Cardiovascular_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
110.01 kB
Formato
Adobe PDF
|
110.01 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
